You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

McKesson
Harvard Business School
Colorcon
Express Scripts
Baxter
Boehringer Ingelheim

Last Updated: May 13, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Relamorelin

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the drug development status for Relamorelin?

Relamorelin is an investigational drug.

There have been 8 clinical trials for Relamorelin. The most recent clinical trial was a Phase 2 trial, which was initiated on January 24th 2018.

The most common disease conditions in clinical trials are Gastroparesis, Diabetes Mellitus, and Constipation. The leading clinical trial sponsors are Allergan, Motus Therapeutics, Inc., and Mayo Clinic.

There are six US patents protecting this investigational drug and twenty-six international patents.

Recent Clinical Trials for Relamorelin
TitleSponsorPhase
Diabetic Gastroparesis Study 05AllerganPhase 3
Study to Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis Study 02AllerganPhase 3
A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 03AllerganPhase 3

See all Relamorelin clinical trials

Clinical Trial Summary for Relamorelin

Top disease conditions for Relamorelin
Top clinical trial sponsors for Relamorelin

See all Relamorelin clinical trials

US Patents for Relamorelin

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Relamorelin   Get Started for $10 Pharmaceutical suspensions containing drug particles, devices for their administration, and methods of their use SynAgile Corporation (Wilson, WY)   Get Started for $10
Relamorelin   Get Started for $10 Use of ghrelin or functional ghrelin receptor agonists to prevent and treat stress-sensitive psychiatric illness Massachusetts Institute of Technology (Cambridge, MA)   Get Started for $10
Relamorelin   Get Started for $10 Pharmaceutical suspensions containing drug particles, devices for their administration, and methods of their use SynAgile Corporation (Wilson, WY)   Get Started for $10
Relamorelin   Get Started for $10 Pharmaceutical suspensions containing drug particles, devices for their administration, and methods of their use SynAgile Corporation (Wilson, WY)   Get Started for $10
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Relamorelin

Drugname Country Document Number Estimated Expiration Related US Patent
Relamorelin Australia AU2016258179 2035-05-06   Get Started for $10
Relamorelin Brazil BR112017023674 2035-05-06   Get Started for $10
Relamorelin Canada CA2984494 2035-05-06   Get Started for $10
Relamorelin China CN107847722 2035-05-06   Get Started for $10
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Harvard Business School
McKinsey
Express Scripts
Baxter
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.